Biomet Inc. (NASDAQ:BMET) makes a variety of medical products, such as replacements for knees and hips.
Now, a variety of private equity firms want the company to themselves: Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts and the Texas Pacific Group. What's more, a founder of Biomet, Dane A. Miller, will also be an investor in the deal.
The price tag comes to $10.9 billion. And, it is a lofty valuation. It comes to 21X cash flows and 3.91X sales.
Then again, the company is likely to be sold-off in pieces – so as to pay down the debt load.
The stock didn't move on the news because, well, the company had been "in play" since April when it retained Morgan Stanley as its financial advisor.
Tom Taulli is the author of various books, including the Complete M&A Handbook and operates DealProfiles.com.
Retailers can't wait for Black Friday, open Thursday
Tiffany's serves up solid quarterly earnings
Cramer on BloggingStocks: This bullish retail story looks like a good fit 
